284 related articles for article (PubMed ID: 18451153)
1. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.
Shi J; Orth JD; Mitchison T
Cancer Res; 2008 May; 68(9):3269-76. PubMed ID: 18451153
[TBL] [Abstract][Full Text] [Related]
2. A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models.
Ye XS; Fan L; Van Horn RD; Nakai R; Ohta Y; Akinaga S; Murakata C; Yamashita Y; Yin T; Credille KM; Donoho GP; Merzoug FF; Li H; Aggarwal A; Blanchard K; Westin EH
Mol Cancer Ther; 2015 Nov; 14(11):2463-72. PubMed ID: 26304237
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint.
Chin GM; Herbst R
Mol Cancer Ther; 2006 Oct; 5(10):2580-91. PubMed ID: 17041103
[TBL] [Abstract][Full Text] [Related]
4. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.
Marcus AI; Peters U; Thomas SL; Garrett S; Zelnak A; Kapoor TM; Giannakakou P
J Biol Chem; 2005 Mar; 280(12):11569-77. PubMed ID: 15653676
[TBL] [Abstract][Full Text] [Related]
5. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly.
Huang HC; Shi J; Orth JD; Mitchison TJ
Cancer Cell; 2009 Oct; 16(4):347-58. PubMed ID: 19800579
[TBL] [Abstract][Full Text] [Related]
6. Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate.
Orth JD; Tang Y; Shi J; Loy CT; Amendt C; Wilm C; Zenke FT; Mitchison TJ
Mol Cancer Ther; 2008 Nov; 7(11):3480-9. PubMed ID: 18974392
[TBL] [Abstract][Full Text] [Related]
7. Kinesin motor proteins as targets for cancer therapy.
Huszar D; Theoclitou ME; Skolnik J; Herbst R
Cancer Metastasis Rev; 2009 Jun; 28(1-2):197-208. PubMed ID: 19156502
[TBL] [Abstract][Full Text] [Related]
8. Mitotic slippage and expression of survivin are linked to differential sensitivity of human cancer cell-lines to the Kinesin-5 inhibitor monastrol.
Asraf H; Avunie-Masala R; Hershfinkel M; Gheber L
PLoS One; 2015; 10(6):e0129255. PubMed ID: 26035434
[TBL] [Abstract][Full Text] [Related]
9. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.
Nakai R; Iida S; Takahashi T; Tsujita T; Okamoto S; Takada C; Akasaka K; Ichikawa S; Ishida H; Kusaka H; Akinaga S; Murakata C; Honda S; Nitta M; Saya H; Yamashita Y
Cancer Res; 2009 May; 69(9):3901-9. PubMed ID: 19351824
[TBL] [Abstract][Full Text] [Related]
10. Targeting mitosis for anti-cancer therapy.
Sudakin V; Yen TJ
BioDrugs; 2007; 21(4):225-33. PubMed ID: 17628120
[TBL] [Abstract][Full Text] [Related]
11. Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance.
Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2021 Feb; 184():114364. PubMed ID: 33310050
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines.
Ling YH; Jiang JD; Holland JF; Perez-Soler R
Mol Pharmacol; 2002 Sep; 62(3):529-38. PubMed ID: 12181429
[TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage.
Tao W; South VJ; Zhang Y; Davide JP; Farrell L; Kohl NE; Sepp-Lorenzino L; Lobell RB
Cancer Cell; 2005 Jul; 8(1):49-59. PubMed ID: 16023598
[TBL] [Abstract][Full Text] [Related]
14. Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic.
Shi J; Mitchison TJ
Endocr Relat Cancer; 2017 Sep; 24(9):T83-T96. PubMed ID: 28249963
[TBL] [Abstract][Full Text] [Related]
15. CPUYJ039, a newly synthesized benzimidazole-based compound, is proved to be a novel inducer of apoptosis in HCT116 cells with potent KSP inhibitory activity.
Jiang C; Yang L; Wu WT; Guo QL; You QD
J Pharm Pharmacol; 2011 Nov; 63(11):1462-9. PubMed ID: 21988427
[TBL] [Abstract][Full Text] [Related]
16. An intermittent live cell imaging screen for siRNA enhancers and suppressors of a kinesin-5 inhibitor.
Tsui M; Xie T; Orth JD; Carpenter AE; Rudnicki S; Kim S; Shamu CE; Mitchison TJ
PLoS One; 2009 Oct; 4(10):e7339. PubMed ID: 19802393
[TBL] [Abstract][Full Text] [Related]
17. Post-slippage multinucleation renders cytotoxic variation in anti-mitotic drugs that target the microtubules or mitotic spindle.
Zhu Y; Zhou Y; Shi J
Cell Cycle; 2014; 13(11):1756-64. PubMed ID: 24694730
[TBL] [Abstract][Full Text] [Related]
18. Phenothiazine and carbazole-related compounds inhibit mitotic kinesin Eg5 and trigger apoptosis in transformed culture cells.
Okumura H; Nakazawa J; Tsuganezawa K; Usui T; Osada H; Matsumoto T; Tanaka A; Yokoyama S
Toxicol Lett; 2006 Sep; 166(1):44-52. PubMed ID: 16814965
[TBL] [Abstract][Full Text] [Related]
19. Recent advances of kinesin motor inhibitors and their clinical progress.
Voultsiadou A; Sarli V
Rev Recent Clin Trials; 2011 Sep; 6(3):271-7. PubMed ID: 21682672
[TBL] [Abstract][Full Text] [Related]
20. Nuclear Lamin A/C Expression Is a Key Determinant of Paclitaxel Sensitivity.
Smith ER; Leal J; Amaya C; Li B; Xu XX
Mol Cell Biol; 2021 Jun; 41(7):e0064820. PubMed ID: 33972393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
